Allarity Therapeutics ends equity line of credit with Tumim Stone Capital

Allarity Therapeutics filed a prospectus supplement dated October 30, 2026 stating that it had terminated the Purchase Agreement effective October 28, 2026.¹ The filing amends an earlier prospectus supplement dated January 28, 2026 and an accompanying prospectus dated December 5, 2025, which had covered the offer and sale by the company of up to $6,000,000 of shares of common stock to Tumim Stone Capital LLC pursuant to a Common Stock Purchase Agreement dated January 28, 2026.¹

As a result of the termination, the primary offering of additional shares under the original prospectus supplement has been terminated.¹ The company said it will not offer or sell any further shares to Tumim under the agreement or that prospectus supplement, and the earlier document can no longer be used to support any new primary sales to Tumim.¹

The filing clarifies that the termination is limited in scope. It only ends the primary offering of new shares to Tumim and does not affect any resale registration that may still apply to shares already issued and sold to Tumim under the earlier agreement.¹ Allarity also said the action does not withdraw or terminate its Form S-3 registration statement, File No. 333-291906, or the base prospectus that accompanies it.¹

The company instructed investors to read the new supplement together with the original prospectus supplement and accompanying prospectus, noting that aside from the changes described, the earlier documents remain unchanged.¹ Allarity pointed readers to the risk factors sections of those earlier filings for further detail.